New pill shows promise against Hard-to-Treat cancers
Disease control
Ongoing
This study tests an experimental oral drug, IMM-1-104, in people with advanced solid tumors that have RAS mutations. The goal is to find a safe dose and see if it can shrink tumors, either alone or with other approved drugs. About 209 adults with pancreatic cancer, melanoma, or l…
Phase: PHASE1, PHASE2 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC